190 related articles for article (PubMed ID: 36814559)
1. A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs.
Zhou SZ; Pan YL; Deng QC; Yin CJ; Zhou DJ; Liu ML; Zhou J; Wu XJ
J Oncol; 2023; 2023():7797710. PubMed ID: 36814559
[TBL] [Abstract][Full Text] [Related]
2. m6A-related lncRNAs are potential biomarkers for the prognosis of COAD patients.
Xu C; He T; Shao X; Gao L; Cao L
Front Oncol; 2022; 12():920023. PubMed ID: 36119534
[TBL] [Abstract][Full Text] [Related]
3. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients.
Zhang P; Liu G; Lu L
Front Cell Dev Biol; 2021; 9():703629. PubMed ID: 34336856
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
5. Potential Prognostic Value of a Seven m6A-Related LncRNAs Signature and the Correlative Immune Infiltration in Colon Adenocarcinoma.
Chai XK; Qi W; Zou CY; He CX; Su M; Zhao DQ
Front Genet; 2021; 12():774010. PubMed ID: 35003214
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
7. lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer.
Kuang F; Luo D; Zhou M; Du J; Yang J
Dis Markers; 2022; 2022():4872001. PubMed ID: 36277972
[TBL] [Abstract][Full Text] [Related]
8. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
9. Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma.
Lin W; Tan ZY; Fang XC
SLAS Technol; 2024 Feb; 29(1):100101. PubMed ID: 37541541
[TBL] [Abstract][Full Text] [Related]
10. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
Front Oncol; 2021; 11():663263. PubMed ID: 34123820
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
12. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
14. Constructing a novel signature and predicting the immune landscape of colon cancer using N6-methylandenosine-related lncRNAs.
Wang Y; Zhang D; Li Y; Wu Y; Ma H; Jiang X; Fu L; Zhang G; Wang H; Liu X; Cai H
Front Genet; 2023; 14():906346. PubMed ID: 37396046
[No Abstract] [Full Text] [Related]
15. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.
Chen S; Li X; Guo L; Zhang J; Li L; Wang X; Zhu Y; Wang J
J BUON; 2021; 26(5):1931-1941. PubMed ID: 34761602
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
18. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
19. Screening of m6A gene-related lncRNAs in colon adenocarcinoma and construction of a prognostic prediction model.
Jin LP; Sun YW; Liu T; Tai JD
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10462-10471. PubMed ID: 37975370
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
